Stephens Keeps a Buy Rating on Mednax Inc (MD)

By Ryan Adsit

In a report issued on November 2, Dana Hambly from Stephens reiterated a Buy rating on Mednax Inc (MDResearch Report), with a price target of $45. The company’s shares closed on Friday at $39.24, close to its 52-week low of $37.26.

According to, Hambly is a 4-star analyst with an average return of 10.9% and a 65.4% success rate. Hambly covers the Services sector, focusing on stocks such as AMN Healthcare Services Inc, Cross Country Healthcare, and Capital Senior Living.

Currently, the analyst consensus on Mednax Inc is a Moderate Buy with an average price target of $46.57.

See today’s analyst top recommended stocks >>

Based on Mednax Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $65.58 million. In comparison, last year the company had a net profit of $65.88 million.

Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

MEDNAX, Inc. provides physician services including newborn, anesthesia, maternal-fetal, tele radiology, pediatric cardiology and other pediatric subspecialty care. The company’s solution include anesthesiology & pain management, prenatal, neonatal, pediatric, radiology, tele radiology, revenue cycle management and perioperative improvement consulting.